<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04195828</url>
  </required_header>
  <id_info>
    <org_study_id>Arise-FJ-G005</org_study_id>
    <nct_id>NCT04195828</nct_id>
  </id_info>
  <brief_title>Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer</brief_title>
  <official_title>Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer: an Multicenter, Open, Randomized, Controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical efficacy and safety of camrelizumab combined with apatinib mesylate,&#xD;
      nab-paclitaxel and S-1&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathologic complete response</measure>
    <time_frame>4 months</time_frame>
    <description>pathologic complete response（pCR）</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>4 months</time_frame>
    <description>Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>4 months</time_frame>
    <description>The surgical procedure was total or subtotal gastrectomy with 3 weeks after total neoadjuvant therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Camrelizumab + Apatinib + nab-paclitaxel +S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camrelizumab combined with Apatinib mesylate tablets, nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nab-paclitaxel +S-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg.</description>
    <arm_group_label>Camrelizumab + Apatinib + nab-paclitaxel +S-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib Mesylate</intervention_name>
    <description>Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday。</description>
    <arm_group_label>Camrelizumab + Apatinib + nab-paclitaxel +S-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2.</description>
    <arm_group_label>Camrelizumab + Apatinib + nab-paclitaxel +S-1</arm_group_label>
    <arm_group_label>nab-paclitaxel +S-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S1</intervention_name>
    <description>S-1 was calculated according to body surface area , P.O., bid, d1-d14。And the dosage according body surface area:&lt;1.25m2, 40mg every time;1.25-1.5m2,50mg every time; &gt;1.5m2, 60mg every time</description>
    <arm_group_label>Camrelizumab + Apatinib + nab-paclitaxel +S-1</arm_group_label>
    <arm_group_label>nab-paclitaxel +S-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-70 years of age&#xD;
&#xD;
          -  Gastric adenocarcinoma was confirmed by pathology（ including histology or cytology）。&#xD;
&#xD;
          -  CT/MRI,PET-CT or laparoscopic exploration were used to confirm the diagnosis of&#xD;
             gastric cancer staging as cT2-4a and/or N+ and M0 before operation.&#xD;
&#xD;
          -  measurable lesions at least should be detected by CT/MRI examination in accordance&#xD;
             with the RECIST1.1.（CT scan of tumor lesion length≥10mm，CT scan short&#xD;
             diameter≥15mm，scan slice thicknes 5mm）&#xD;
&#xD;
          -  ECOG（Eastern Cooperative Oncology Group）PS（Performance Status）:0-1 scores;&#xD;
&#xD;
          -  the expected survival time is more than 12 weeks&#xD;
&#xD;
          -  the main organ function is normal, which should meet the following criteria:&#xD;
&#xD;
             (1) blood routine examination standards should be met（no blood transfusion within 14&#xD;
             days）&#xD;
&#xD;
             a．HB≥ 100g/L b. WBC≥3×109/L c. ANC≥1.5×109/L d. PLT≥100×109/L （2）biochemical&#xD;
             examination shall comply with the following criteria：&#xD;
&#xD;
               1. BIL&lt;1.5 normal upper limit ULN&#xD;
&#xD;
               2. ALT and AST&lt;2.5 ULN,GPT≤1.5×ULN&#xD;
&#xD;
               3. Cr≤1 ULN，CCR（creatinine clearance rate）&gt;60ml/min(Cockcroft-Gault formula)&#xD;
&#xD;
          -  women of childbearing age must have a pregnancy test in 7 days before entering the&#xD;
             group (in serum), and the results were negative, and willing to use appropriate&#xD;
             contraception during the study period and the last 8 weeks after giving drug test; men&#xD;
             should have the surgical sterilization, or adopt the appropriate contraceptive methods&#xD;
             during the test and the last 8 weeks after giving drug test。&#xD;
&#xD;
          -  No other clinical studies were conducted before and during the treatment&#xD;
&#xD;
          -  participants is willing to participate in this study, sign the informed consent, have&#xD;
             good compliance, cooperate with follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous history of chemotherapy, radiotherapy, targeted drug therapy or immunotherapy&#xD;
&#xD;
          -  Patients with contraindications for surgical treatment and chemotherapy or whose&#xD;
             physical condition and organ function do not allow for larger abdominal surgery&#xD;
&#xD;
          -  patients with metastasis&#xD;
&#xD;
          -  Having any active autoimmune diseases or a history of autoimmune diseases (such as&#xD;
             interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation,&#xD;
             vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism, including but not&#xD;
             limited to these diseases or syndromes); Patients with vitiligo or cured childhood&#xD;
             asthma/allergies who did not need any intervention in adulthood were excluded;&#xD;
             Autoimmune hypothyroidism treated with a stable dose of thyroid replacement hormone;&#xD;
             Type 1 diabetes with stable doses of insulin&#xD;
&#xD;
          -  A history of immunodeficiency, including HIV testing positive, or other acquired or&#xD;
             congenital immunodeficiency disorders, or a history of organ transplantation and&#xD;
             allogeneic bone marrow transplantation&#xD;
&#xD;
          -  Accompanied by serious heart, lung, liver, kidney disease; Have nerve, mental disease;&#xD;
             Jaundice or obstruction of the digestive tract with severe infection&#xD;
&#xD;
          -  pregnant or lactating women&#xD;
&#xD;
          -  The blood pressure of patients with hypertension cannot be reduced to the normal range&#xD;
             by the antihypertensive drugs (systolic pressure &gt;140 mmHg, diastolic pressure &gt;90&#xD;
             mmHg)&#xD;
&#xD;
          -  With Ⅰ magnitude of coronary heart disease, arrhythmia (including QTc protracted&#xD;
             between male &gt; 450 ms, women &gt; 470 ms) and cardiac insufficiency&#xD;
&#xD;
          -  Patients have a clear tendency with gastrointestinal bleeding, including the following&#xD;
             situation: local active ulcerative lesions, and fecal occult blood (+ +); with melena&#xD;
             and hematemesis history in 2 months; and patients with fecal occult blood (+) and&#xD;
             unresected gastric primary tumor; patients with the risk of bleeding should take the&#xD;
             gastroscopy test, if it is the gastric cancer, and researchers believe that may&#xD;
             results in massive digestive tract hemorrhage；coagulation dysfunction&#xD;
             (INR(international normalized ratio)&gt;1.5, APTT(activated partial thromboplastin&#xD;
             time)&gt;1.5 ULN), with bleeding tendency;&#xD;
&#xD;
          -  Subjects have failed to control good cardiovascular clinical symptoms or disease,&#xD;
             including but not limited to: such as: (1) the NYHA class II heart failure (2) above&#xD;
             unstable angina pectoris (3) occurred within 1 year (4) have clinical significance of&#xD;
             myocardial infarction (mi) room sex or ventricular arrhythmias without clinical&#xD;
             intervention on or after clinical intervention is still poorly controlled&#xD;
&#xD;
          -  History of interstitial lung disease (except radiation pneumonia without hormone&#xD;
             therapy), and history of non-infectious pneumonia&#xD;
&#xD;
          -  Patients are positive of urine protein (urine protein detection 2+ or above, or 24&#xD;
             hours urine protein quantitative &gt;1.0g);&#xD;
&#xD;
          -  A person who has previously been allergic to any component of camrilizumab or to any&#xD;
             component of the drug under study&#xD;
&#xD;
          -  The researchers consider those who were not suitable for inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changming Huang, Professor</last_name>
      <phone>8613805069676</phone>
      <email>hcmlr2002@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University Union Hospital</investigator_affiliation>
    <investigator_full_name>Chang-Ming Huang, Prof.</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

